Drug Development Pipeline
Back to the Drug Development Pipeline
ARO-ENaC is a drug intended to thin airway surface liquid. It is designed to block the function of the sodium (Na+) channel found in the lungs. These channels move sodium and water away from the airway surface. Blocking these channels may help maintain fluid within the airways to improve mucus clearance.
A phase 1 study to test the safety and tolerability of ARO-ENaC was completed. No further development in CF is planned at this time.
This program was sponsored by Arrowhead Pharmaceuticals.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More